A set of genes associated with the interferon-γ response of lung cancer patients undergoing α-galactosylceramide-pulsed dendritic cell therapy

Cancer Science

Volumn 101, Issue 11, 2010, Pages 2333-2340

  Okita, Kohsuke ^a,b   Motohashi, Shinichiro ^a   Shinnakasu, Ryo ^a   Nagato, Kaoru ^a   Yamasaki, Kazuki ^a   Sato, Yasunori ^c   Kitamura, Hiroshi ^d   Hijikata, Atsushi ^d   Yamashita, Masakatsu ^a   Shimizu, Kanako ^e   Fujii, Shin Ichiro ^f   Ohara, Osamu ^d   Taniguchi, Masaru ^g   Sakaida, Isao ^b   Nakayama, Toshinori ^a  

^a CHIBA UNIVERSITY   (Japan)

^b YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c CHIBA UNIVERSITY HOSPITAL   (Japan)

^d Laboratory for Immunogenomics   (Japan)

^e Research Unit for Therepeutic Model   (Japan)

^f Research Unit for Cellular Immunotherapy   (Japan)

^g Institute of Physical and Chemical Research   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD56 ANTIGEN; COMPLEMENTARY DNA; DIHYDROPYRIMIDINASE; DIHYDROPYRIMIDINASE LIKE 3; GAMMA INTERFERON; LEUKOTRIENE B4; LEUKOTRIENE B4 12 HYDROXYDEHYDROGENASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; CD3+ T LYMPHOCYTE; CELL THERAPY; CYTOKINE PRODUCTION; DENDRITIC CELL; DENDRITIC CELL THERAPY; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HUMAN; IMMUNOTHERAPY; LUNG CANCER; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; ALCOHOL OXIDOREDUCTASES; ANTIGENS, CD3; ANTIGENS, CD56; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLUSTER ANALYSIS; DENDRITIC CELLS; FEMALE; GALACTOSYLCERAMIDES; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUSCLE PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; T-LYMPHOCYTES;

EID: 78049446499     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01696.x     Document Type: Article

References (37)

1. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-8.
2. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-103.
3. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004; 350: 379-92.
4. Huisman C, Smit EF, Giaccone G, Postmus PE. Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J Clin Oncol 2000; 18: 3722-30.
5. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. The regulatory role of Vα14 NKT cells in innate and acquired immune response. Annu Rev Immunol 2003; 21: 483-513.
6. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 2007; 25: 297-336.
7. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol 2004; 4: 231-7.
8. Kawano T, Cui J, Koezuka Y et al. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 1997; 278: 1626-9.
9. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 2003; 198: 267-79.
10. Smyth MJ, Crowe NY, Pellicci DG et al. Sequential production of interferon-γ by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of α-galactosylceramide. Blood 2002; 99: 1259-66.
11. Eberl G, MacDonald HR. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur J Immunol 2000; 30: 985-92.
12. Carnaud C, Lee D, Donnars O et al. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 1999; 163: 4647-50.
13. Taniguchi M, Seino K, Nakayama T. The NKT cell system: bridging innate and acquired immunity. Nat Immunol 2003; 4: 1164-5.
14. Ishikawa A, Motohashi S, Ishikawa E, et al. A phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2005; 11: 1910-7.
15. Motohashi S, Nagato K, Kunii N et al. A phase I-II study of α-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol 2009; 182: 2492-501.
16. Hubbell E, Liu WM, Mei R. Robust estimators for expression analysis. Bioinformatics 2002; 18: 1585-92.
17. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003; 31: e15.
18. Kimura YM, Hosokawa H, Yamashita M et al. Regulation of T helper type 2 cell differentiation by murine Schnurri-2. J Exp Med 2005; 201: 397-408.
19. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988; 240: 1285-93.
20. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39: 561-77.
21. Hijikata A, Kitamura H, Kimura Y et al. Construction of an open-access database that integrates cross-reference information from the transcriptome and proteome of immune cells. Bioinformatics 2007; 23: 2934-41.
22. Hori T, Yokomizo T, Ago H et al. Structural basis of leukotriene B4 12-hydroxydehydrogenase/15-Oxo-prostaglandin 13-reductase catalytic mechanism and a possible Src homology 3 domain binding loop. J Biol Chem 2004; 279: 22615-23.
23. Hilkens CM, Snijders A, Snijdewint FG, Wierenga EA, Kapsenberg ML. Modulation of T-cell cytokine secretion by accessory cell-derived products. Eur Respir J Suppl 1996; 22: 90s-4s.
24. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol 2002; 23: 144-50.
25. Schultz IJ, Wester K, Straatman H et al. Prediction of recurrence in Ta urothelial cell carcinoma by real-time quantitative PCR analysis: a microarray validation study. Int J Cancer 2006; 119: 1915-9.
26. Dyrskjot L, Thykjaer T, Kruhoffer M et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 2003; 33: 90-6.
27. Kowara R, Moraleja KL, Chakravarthy B. PLA(2) signaling is involved in calpain-mediated degradation of synaptic dihydropyrimidinase-like 3 protein in response to NMDA excitotoxicity. Neurosci Lett 2008; 430: 197-202.
28. Rouzaut A, Lopez-Moratalla N, De Miguel C. Differential gene expression in the activation and maturation of human monocytes. Arch Biochem Biophys 2000; 374: 153-60.
29. Hamajima N, Matsuda K, Sakata S, Tamaki N, Sasaki M, Nonaka M. A novel gene family defined by human dihydropyrimidinase and three related proteins with differential tissue distribution. Gene 1996; 180: 157-63.
30. Charrier E, Reibel S, Rogemond V, Aguera M, Thomasset N, Honnorat J. Collapsin response mediator proteins (CRMPs): involvement in nervous system development and adult neurodegenerative disorders. Mol Neurobiol 2003; 28: 51-64.
31. Motohashi S, Nakayama T. Clinical applications of natural killer T cell-based immunotherapy for cancer. Cancer Sci 2008; 99: 638-45.
32. Fujii S, Motohashi S, Shimizu K, Nakayama T, Yoshiga Y, Taniguchi M. Adjuvant activity mediated by iNKT cells. Semin Immunol 2010; 22: 97-102.
33. Singhal S, Miller D, Ramalingam S, Sun SY. Gene expression profiling of non-small cell lung cancer. Lung Cancer 2008; 60: 313-24.
34. Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008; 26: 983-94.
35. Fan T, Li R, Todd NW et al. Up-regulation of 14-3-3ζ in lung cancer and its implication as prognostic and therapeutic target. Cancer Res 2007; 67: 7901-6.
36. Albert JM, Gonzalez A, Massion PP et al. Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 1845-51.
37. Taniwaki M, Takano A, Ishikawa N et al. Activation of KIF4A as a prognostic biomarker and therapeutic target for lung cancer. Clin Cancer Res 2007; 13: 6624-31.